281 |
Assessing Patients' and Radiation Therapists’ Perceptions of Safety in Radiation Therapy and Using a Patient-provider Collaborative Checklist to Engage PatientsCrupi, Michael Kyle 21 November 2013 (has links)
Approximately 52% of cancer patients require radiation therapy during the progression of their illness. Radiation therapy is a safe procedure; however, errors may occur and have the potential to harm patients. Recent studies have looked at patient engagement as a means of preventing errors in healthcare. Through interviews and focus groups, this study looks at patients’ and radiation therapists’ current perceptions of safety in radiation therapy and whether they feel that patient engagement in the form of a patient-provider collaborative checklist can improve its safety or the perception of safety. Through workflow observations and literature reviews, a patient-provider collaborative checklist was developed. Furthermore, STAI surveys were conducted to document the progression of patient anxiety through treatment. Feedback from radiation therapists demonstrated their opinions on the usability of the final iteration of the patient-provider collaborative checklist and how it could fit into the clinical setting.
|
282 |
The production and detection of optimized low-Z linear accelerator target beams for image guidance in radiotherapyParsons, David, Parsons, David 22 August 2012 (has links)
Recent work has demonstrated improvement of image quality with low atomic number (Z) linear accelerator (linac) targets and energies as low as 3.5 MV compared to a standard 6 MV therapeutic beam. In this work, the incident electron beam energy has been lowered to energies between 1.90 and 2.35 MeV. The improvement of megavoltage planar image quality with the use of carbon and aluminum linac targets has been assessed compared to a standard 6 MV therapeutic beam.
Common electronic portal imaging devices contain a 1.0 mm copper conversion plate to increase detection efficiency of a therapeutic megavoltage spectrum. When used in imaging with a photon beam generated with a low-Z target, the conversion plate attenuates a substantial proportion of photons in the diagnostic range, thereby reducing the achievable image quality. Image quality as a function of copper plate thickness has been assessed for planar imaging and cone beam computed tomography.
|
283 |
Development, Characterization and Validation of Trastuzumab-Modified Gold Nanoparticles for Molecularly Targeted Radiosensitization of Breast CanceChattopadhyay, Niladri 12 December 2013 (has links)
The overexpression of the human epidermal growth factor receptor-2 (HER-2) in 20-25% of human breast cancers was investigated as a target for development of a gold nanoparticle (AuNP) based radiosensitizer for improving the efficacy of neoadjuvant X-radiation therapy of the disease. HER-2 targeted AuNPs were developed by covalently conjugating trastuzumab, a Health Canada approved monoclonal antibody for the treatment of HER-2-overexpressing breast cancer, to 30 nm AuNPs. Trastuzumab conjugated AuNPs were efficiently internalized by HER-2-overexpressing breast cancer cells (as assessed by darkfield microscopy and transmission electron microscopy) and increased DNA damage from X-radiation in these cells by more than 5-fold. To optimize delivery of AuNPs to HER-2-overexpressing tumors, high resolution microSPECT/CT imaging was used to track the in vivo fate of 111In-labelled non-targeted and HER-2 targeted AuNPs following intravenous (i.v.) or intratumoral (i.t.) injection. For i.v. injection, the effects of GdCl3 (for deactivation of macrophages) and non-specific (anti-CD20) antibody rituximab (for blocking of Fc mediated liver and spleen uptake) were studied. It was found that HER-2 targeting via attachment of trastuzumab paradoxically decreased tumor uptake as a result of faster elimination of the targeted AuNPs from the blood while improving internalization in HER-2-positive tumor cells as compared to non-targeted AuNPs. This phenomenon could be attributed to Fc-mediated recognition and subsequent sequestration of trastuzumab conjugated AuNP by the reticuloendothelial system (RES). Blocking of the RES did not increase tumor uptake of either HER-2 targeted or non-targeted AuNPs. Following i.t. injection, our results suggest that Au-NTs redistribute over time and traffick to the liver via the ipsilateral axillary lymph node leading to comparable exposure as seen with i.v. administration. In contrast, targeted AuNPs are bound and internalized by HER-2-overexpressing tumor cells following i.t. injection, with a lower proportion of AuNPs redistributing to normal tissues. In vivo, the combination of HER-2 targeted AuNPs injected i.t. and X-radiation (11 Gy) yielded a 46% decrease in tumor size over a 4 month period in contrast to an 11.5% increase in tumor size for X-radiation treatment alone. Toxicology studies (evaluated through complete blood cell counts, by serum transaminase and creatinine measurements and by monitoring the body weight) demonstrated no apparent normal organ toxicity from the combination of HER-2 targeted AuNPs and X-radiation. These results are promising for the clinical translation of HER-2-targeted AuNPs for radiosensitization of tumors to X-radiation.
|
284 |
Regulation of collagen type I production by ionizing radiation and transforming growth factor-β1 in primary human skin fibroblasts derived from early stage breast cancer patients in relation to acute radiation-induced toxicityWang, Ying Wang Unknown Date
No description available.
|
285 |
Assessing Patients' and Radiation Therapists’ Perceptions of Safety in Radiation Therapy and Using a Patient-provider Collaborative Checklist to Engage PatientsCrupi, Michael Kyle 21 November 2013 (has links)
Approximately 52% of cancer patients require radiation therapy during the progression of their illness. Radiation therapy is a safe procedure; however, errors may occur and have the potential to harm patients. Recent studies have looked at patient engagement as a means of preventing errors in healthcare. Through interviews and focus groups, this study looks at patients’ and radiation therapists’ current perceptions of safety in radiation therapy and whether they feel that patient engagement in the form of a patient-provider collaborative checklist can improve its safety or the perception of safety. Through workflow observations and literature reviews, a patient-provider collaborative checklist was developed. Furthermore, STAI surveys were conducted to document the progression of patient anxiety through treatment. Feedback from radiation therapists demonstrated their opinions on the usability of the final iteration of the patient-provider collaborative checklist and how it could fit into the clinical setting.
|
286 |
Development, Characterization and Validation of Trastuzumab-Modified Gold Nanoparticles for Molecularly Targeted Radiosensitization of Breast CanceChattopadhyay, Niladri 12 December 2013 (has links)
The overexpression of the human epidermal growth factor receptor-2 (HER-2) in 20-25% of human breast cancers was investigated as a target for development of a gold nanoparticle (AuNP) based radiosensitizer for improving the efficacy of neoadjuvant X-radiation therapy of the disease. HER-2 targeted AuNPs were developed by covalently conjugating trastuzumab, a Health Canada approved monoclonal antibody for the treatment of HER-2-overexpressing breast cancer, to 30 nm AuNPs. Trastuzumab conjugated AuNPs were efficiently internalized by HER-2-overexpressing breast cancer cells (as assessed by darkfield microscopy and transmission electron microscopy) and increased DNA damage from X-radiation in these cells by more than 5-fold. To optimize delivery of AuNPs to HER-2-overexpressing tumors, high resolution microSPECT/CT imaging was used to track the in vivo fate of 111In-labelled non-targeted and HER-2 targeted AuNPs following intravenous (i.v.) or intratumoral (i.t.) injection. For i.v. injection, the effects of GdCl3 (for deactivation of macrophages) and non-specific (anti-CD20) antibody rituximab (for blocking of Fc mediated liver and spleen uptake) were studied. It was found that HER-2 targeting via attachment of trastuzumab paradoxically decreased tumor uptake as a result of faster elimination of the targeted AuNPs from the blood while improving internalization in HER-2-positive tumor cells as compared to non-targeted AuNPs. This phenomenon could be attributed to Fc-mediated recognition and subsequent sequestration of trastuzumab conjugated AuNP by the reticuloendothelial system (RES). Blocking of the RES did not increase tumor uptake of either HER-2 targeted or non-targeted AuNPs. Following i.t. injection, our results suggest that Au-NTs redistribute over time and traffick to the liver via the ipsilateral axillary lymph node leading to comparable exposure as seen with i.v. administration. In contrast, targeted AuNPs are bound and internalized by HER-2-overexpressing tumor cells following i.t. injection, with a lower proportion of AuNPs redistributing to normal tissues. In vivo, the combination of HER-2 targeted AuNPs injected i.t. and X-radiation (11 Gy) yielded a 46% decrease in tumor size over a 4 month period in contrast to an 11.5% increase in tumor size for X-radiation treatment alone. Toxicology studies (evaluated through complete blood cell counts, by serum transaminase and creatinine measurements and by monitoring the body weight) demonstrated no apparent normal organ toxicity from the combination of HER-2 targeted AuNPs and X-radiation. These results are promising for the clinical translation of HER-2-targeted AuNPs for radiosensitization of tumors to X-radiation.
|
287 |
Benchmarking a new three-dimensional ultrasound system for prostate image guided radiation therapyJohnston, Holly A. 23 April 2008 (has links)
Image guided radiation therapy (IGRT) is a new type of radiotherapy used to deliver lethal doses of radiation to mobile tumors, while preventing surrounding healthy structures from receiving high doses of radiation. It relies on image guidance to track the tumor and ensure its prescribed position in the radiation beam. The main goal
of this work was to determine if a new three-dimensional ultrasound (3D US) image
guidance device, called the Restitu System, could safely replace (or be used interchangeably with) an existing method involving x-ray images of implanted fiducial
markers (FMs) for prostate IGRT. Using comparison statistics called 95 % limits of
agreement (LOA), it was found that the new 3D US system did not produce measurements that agreed sufficiently closely to those made using the FM technique, and therefore, could not safely replace FMs for prostate IGRT. Ultrasound image quality and user variability were determined to have a significant impact on the agreement between the two methods. It was further shown that using the Restitu System offered no significant clinical advantages over a conventional patient re-positioning technique.
|
288 |
Monte Carlo dose calculations in advanced radiotherapyBush, Karl Kenneth 15 September 2009 (has links)
The remarkable accuracy of Monte Carlo (MC) dose calculation algorithms has led to the widely accepted view that these methods should and will play a central role in the radiotherapy treatment verification and planning of the future. The advantages of using MC clinically are particularly evident for radiation fields passing through inhomogeneities, such as lung and air cavities, and for small fields, including those used in today's advanced intensity modulated radiotherapy techniques. Many investigators have reported significant dosimetric differences between MC and conventional dose calculations in such complex situations, and have demonstrated experimentally the unmatched ability of MC calculations in modeling charged particle disequilibrium. The advantages of using MC dose calculations do come at a cost. The nature of MC dose calculations require a highly detailed, in-depth representation of the physical system (accelerator head geometry/composition, anatomical patient geometry/composition and particle interaction physics) to allow accurate modeling of external beam radiation therapy treatments. To perform such simulations is computationally demanding and has only recently become feasible within mainstream radiotherapy practices. In addition, the output of the accelerator head simulation can be highly sensitive to inaccuracies within a model that may not be known with sufficient detail.
The goal of this dissertation is to both improve and advance the implementation of MC dose calculations in modern external beam radiotherapy. To begin, a novel method is proposed to fine-tune the output of an accelerator model to better represent the measured output. In this method an intensity distribution of the electron beam incident on the model is inferred by employing a simulated annealing algorithm. The method allows an investigation of arbitrary electron beam intensity distributions and is not restricted to the commonly assumed Gaussian intensity.
In a second component of this dissertation the design, implementation and evaluation of a technique for reducing a latent variance inherent from the recycling of phase space particle tracks in a simulation is presented. In the technique a random azimuthal rotation about the beam's central axis is applied to each recycled particle, achieving a significant reduction of the latent variance.
In a third component, the dissertation presents the first MC modeling of Varian's new RapidArc delivery system and a comparison of dose calculations with the Eclipse treatment planning system. A total of four arc plans are compared including an oropharynx patient phantom containing tissue inhomogeneities.
Finally, in a step toward introducing MC dose calculation into the planning of treatments such as RapidArc, a technique is presented to feasibly generate and store a large set of MC calculated dose distributions. A novel 3-D dyadic multi-resolution (MR) decomposition algorithm is presented and the compressibility of the dose data using this algorithm is investigated. The presented MC beamlet generation method, in conjunction with the presented 3-D data MR decomposition, represents a viable means to introduce MC dose calculation in the planning and optimization stages of advanced radiotherapy.
|
289 |
Intrakavitäre High-Dose-Rate-Brachytherapie zur Behandlung von Nasentumoren beim HundKrastel, Dorothee 24 June 2010 (has links) (PDF)
Für die Therapie maligner intranasaler Neoplasien beim Hund existieren nur mäßig be-friedigende Behandlungsstrategien. Als Therapiemodalität der Wahl wird die Radiothe-rapie angesehen, die gegenwärtig v.a. in Form einer perkutanen Bestrahlung (Telethe-rapie) mit aufwendigen, bis zu 20 Fraktionen umfassenden Protokollen kurativer Intenti-on angewendet wird. Die erreichbaren Überlebenszeiten sind meist limitiert durch das Auftreten eines Rezidivs des Nasentumors innerhalb des Bestrahlungsfeldes, sodass eine Erhöhung der applizierten Gesamtdosis nötig erscheint. Dies ist jedoch im Rahmen einer Teletherapie aufgrund nicht vertretbarer akuter Nebenwirkungen nicht möglich. Alternativ steht die Brachytherapie zur Verfügung, die aufgrund ihrer physikalischen Charakteristika zur besseren Schonung des umliegenden Normalgewebes beiträgt. Ge-genwärtig existieren keine anderen Untersuchungen zur Anwendung der fraktionierten High-Dose-Rate-Brachytherapie bei Nasentumoren des Hundes. Ziel dieser Studie war es daher, die Durchführbarkeit dieser Therapiemodalität beim Hund erstmals zu unter-suchen und die akuten und chronischen Nebenwirkungen sowie die erzielbare progres-sionsfreie Zeit und die Überlebenszeit zu dokumentieren.
Im Zeitraum von 2001 bis 2007 gingen 18 Hunde in die Studie ein. Das diagnostische Vorgehen beinhaltete neben einer klinischen Untersuchung und der Röntgenuntersu-chung von Nase und Thorax auch die kernspintomographische Beurteilung der Nasen-höhlen und eine nachfolgende Rhinoskopie inklusive Biopsie. Die Therapie bestand aus zwei wöchentlichen Fraktionen, bei denen in Vollnarkose über einen in der Nasenhöhle applizierten Katheter mithilfe des Radioisotops 192Iridium jeweils 5 Gy appliziert wurden. Die damit über vier Wochen erreichte Gesamtdosis lag bei 40 Gy, und entsprach damit der biologischen Effizienz einer perkutan applizierten konventionell fraktionierten Ge-samtdosis von circa 60 Gy. Im Anschluss an die Therapie wurden die Hunde monatlich klinisch untersucht und die auftretenden Nebenwirkungen anhand des Radiation Morbi-dity Scores der VRTOG beschrieben. Es wurden außerdem weiterführende Untersu-chungen in Form von MRT, Rhinoskopie und Biopsie durchgeführt. Die aufgetretenen Nebenwirkungen waren mit denen in der Literatur nach Teletherapie beschriebenen vergleichbar, beziehungsweise fielen im Bereich von Augen und Maulschleimhaut ge-ringer aus. Nebenwirkungen im Bereich der Haut traten in Form von Alopezie, Hyper-pigmentation oder Leukotrichie auf. Im Bereich der Nasenschleimhaut zeigten fast alle Hunde eine leichte chronische Rhinitis. Als problematische Nebenwirkungen traten bei drei Patienten Osteoradionekrosen auf, die einer aufwendigeren chirurgischen Versor-gung bedurften. Die mediane progressionsfreie Zeit lag bei 13 Monaten, die mediane Überlebenszeit bei 17 Monaten. Die Adenokarzinome wiesen die längste Überlebens-zeit auf, dies war jedoch aufgrund der insgesamt kleinen Patientenzahl nicht signifikant. Ein Zusammenhang zwischen dem Tumorstadium und der progessionsfreien Zeit oder Überlebenszeit bestand nicht.
Bei dem beschriebenen Protokoll handelt es sich um eine unter klinischen Bedingungen praktikable Therapieform, die mit ihren insgesamt acht Fraktionen für Besitzer und Tier wesentlich weniger belastend ist als teletherapeutische kurative Protokolle mit 12-20 Fraktionen. Gleichzeitig gelingt es, eine Gesamtdosis von verhältnismäßig hoher biolo-gischer Effizienz zu applizieren, ohne jedoch stärkere Nebenwirkungen in Kauf nehmen zu müssen. Im Bereich von Auge und Maulschleimhaut sind die Nebenwirkungen sogar geringer. Bei einem kleinen Teil der Patienten treten jedoch auch hier, ebenso wie nach teletherapeutischen Protokollen, problematische chronische Nebenwirkungen auf, die die Lebensqualität der betroffenen Tiere beeinträchtigen und die einer aufwendigeren Therapie zwingend bedürfen. Die mit diesem Protokoll erreichten Remissions- und Ü-berlebenszeiten sind mit denen aus der Literatur vergleichbar bis tendenziell besser. Aufgrund der oben genannten Vorteile erscheint die vorgestellte Therapie daher als Al-ternative zu Teletherapie bei der Behandlung kaniner Nasentumoren durchaus geeig-net. Weitere Studien mit größeren Patientenzahlen unter Einbeziehung einer anders therapierten Kontrollgruppe sind jedoch notwendig
|
290 |
Cancer treatment optimizationCha, Kyungduck 01 April 2008 (has links)
This dissertation investigates optimization approaches applied to radiation therapy in cancer treatment. Since cancerous cells are surrounded by critical organs and normal tissues, there is conflicting objectives in the treatment design of providing sufficient radiation dose to tumor region, while avoiding normal healthy cells. In general, the goal of radiation therapy is to conform the spatial distribution of the prescribed dose to the tumor volume while minimizing the dose to the surrounding normal structures. A recent advanced technology, using multi-leaf collimator integrated into linear accelerator, provides much better opportunities to achieve this goal: the radiotherapy based on non-uniform radiation beams intensities is called Intensity-Modulated Radiation Therapy.
My dissertation research offers a quadratic mixed integer programming approach to determine optimal beam orientations and beamlets intensity simultaneously. The problems generated from real patient cases are large-scale dense instances due to the physics of dose contributions from beamlets to volume elements. The research highlights computational techniques to improve solution times for these intractable instances. Furthermore,
results from this research will provide plans that are clinically acceptable and superior in plan quality, thus directly improve the curity rate and lower the normal tissue complication for cancer patients.
|
Page generated in 0.0242 seconds